Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial.
D000917:Antibody Formation / Q000187:drug effects; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D003168:Complement Fixation Tests; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D006562:Herpes Zoster / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D014645:Herpesvirus 3, Human / Q000276:immunology; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D007263:Infusions, Parenteral; D007372:Interferons / Q000032:analysis; D008223:Lymphoma / Q000150:complications / Q000276:immunology; D010919:Placebos; D013997:Time Factors
D010919:Placebos; D003561:Cytarabine; D007372:Interferons